Elsevier Launches Updated Drug-Drug Interaction Risk Calculator in Collaboration with Several Pharmaceutical Leaders

ElsevierElsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further refined and extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.

Currently, DDIs account for 3-5 percent of all reported adverse drug reactions in hospitals, and this is only growing as patients today are being prescribed more drugs(1). The DDIRC helps drug developers predict DDIs with greater confidence and make more informed drug safety decisions, much earlier in the drug development process. The 2.0 release has advanced in-product visualization and filters supporting the quick identification of DDI risk. These visualizations are built upon a more comprehensive dataset for more reliable results. The updated tool also improves the ease of submitting dossiers to the FDA and other international medicines agencies.

"Predicting potential drug-drug interaction is a key component of risk management at all stages of clinical development and throughout the drug lifecycle," says Eric Didier, Head of PKPD Department at Pierre Fabre. "Through our cooperation with Elsevier, we believe DDIRC is the perfect tool for addressing this important topic in the most precise and time effective manner, with great visual outputs and complete trackability of input sources."

The DDIRC provides calculations and predictions in a transparent, explainable way, removing the black box around equations using mechanistic static modeling, replicating the physiological processes occurring in the body. The tool enables researchers to track predictions through the development cycle from pre-clinical to phase 3 trials and project manage multiple simulations at the same time. It also assists with inclusion and exclusion criteria for patients in phase 2 and 3 trials to improve safety.

Thibault Géoui, Senior Director Discovery Biology and Predictive Risk Management, Elsevier commented: "In the past, DDIs have been difficult to identify as they were not found in the clinical development process - as patients taking other medicines are often excluded from clinical trials. They are then only discovered when patients experience adverse events in real life situations. However, by using the DDIRC in the drug development process, potential DDIs can be discovered early and adverse reactions in patients post-market can be prevented."

The predictive power of PharmaPendium's DDIRC enables researchers to compare their valuable internal data with external data including public regulatory filings to understand the extent of drug reactions. The DDIRC has been developed in line with the FDA's guidelines for prediction of enzyme-mediated DDI risk to make dossier submissions as straightforward as possible. PharmaPendium's DDIRC 2.0 is now available.

For further information, please visit:
https://www.elsevier.com/solutions/pharmapendium-clinical-data/dmpk

About Elsevier

As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

1. Sourced from: “Preventable Adverse Drug Reactions: A Focus on Drug Interactions.” Silver Spring, MD, USA. © United States Food and Drug Administration, 2018.

Most Popular Now

Virtual Reality could Help to Reduce Pai…

We all feel physical pain in different ways, but people with nerve injuries often have a dysfunctional pain suppression system, making them particularly prone to discomfort. Now researchers have uncovered that...

Early Warning System for Intensive Care …

Life-threatening situations occur time and again in an intensive care unit. To make sure that doctors can intervene in time, a team at the German Heart Center Berlin (DHZB) has...

Philips Partners with Orbita to Develop …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Orbita Inc., an innovative provider of conversational artificial intelligence (AI) solutions for healthcare, announced a partnership agreement...

CliniSys Group Creates Single Brand for …

CliniSys Group has created a single brand for its businesses in the UK and Europe, with a refreshed logo and a new website. The move creates a unified identity for CliniSys...

East Lancashire Signs Deal for Early War…

Thousands of NHS professionals across five hospitals in East Lancashire are to benefit from early warning technology that will help them detect and swiftly respond to deteriorating patients in need...

FDA Grants Oxehealth Vital Signs De Novo…

Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the...

Telemedicine Improves Access to High-Qua…

The American Academy of Sleep Medicine recently published an update on the use of telemedicine for the diagnosis and treatment of sleep disorders to reflect lessons learned from the transition...

DMEA 2021: Digital Health. 100 % Virtual…

7 - 11 June 2021, Berlin, Germany. An entire week dominated by digital healthcare! With that in mind, early in June DMEA 2021 will be kicking off with a wide range...

Philips and NHS Implement the First Regi…

Royal Philips (NYSE: PHG, AEX: PHIA), announced it has supported the NHS' Cheshire and Merseyside consortium [1] to become the first regional hub supplying the United Kingdom's National COVID-19 Chest...

Child Brain Tumours can be Classified by…

Diffusion weighted imaging and machine learning can successfully classify the diagnosis and characteristics of common types of paediatric brain tumours a UK-based multi-centre study, including WMG at the University of...

AI could Crack the Language of Cancer an…

Powerful algorithms used by Netflix, Amazon and Facebook can 'predict' the biological language of cancer and neurodegenerative diseases like Alzheimer's, scientists have found.